Human epidermal growth factor receptor-2 (HER-2) mediates a number of important cellular
activities, and is up-regulated in a diverse set of cancer cell lines, especially breast cancer. Accordingly, HER-2
has been regarded as a common drug target in cancer therapy. Antibodies can serve as ideal candidates for
targeted tumor imaging and drug delivery, due to their inherent affinity and specificity. Advanced by the
development of a wide variety of imaging techniques, antibody-based imaging of HER-2 can allow for early
detection and localization of tumors, as well as monitoring of drug delivery and tissue’s response to drug
treatment. In this review article, antibody-based imaging of HER-2 are summarized and discussed, with an
emphasis on the involved imaging methods.
Keywords: Antibody, drug delivery, magnetic resonance imaging (MRI), near-infrared fluorescence (NIRF) imaging,
photoacoustic tomography (PAT), positron emission tomography (PET), radioimmunoscintigraphy (RIS), singlephoton
emission computed tomography (SPECT).
Rights & PermissionsPrintExport